The C1 domain of Vav3, a novel potential therapeutic target.

[1]  J. Rizo,et al.  Mechanistic insights into neurotransmitter release and presynaptic plasticity from the crystal structure of Munc13-1 C1C2BMUN , 2017, eLife.

[2]  R. Veazey,et al.  In vitro effects of the small-molecule protein kinase C agonists on HIV latency reactivation , 2016, Scientific Reports.

[3]  Megan L. Peach,et al.  Structural Basis for the Failure of the C1 Domain of Ras Guanine Nucleotide Releasing Protein 2 (RasGRP2) to Bind Phorbol Ester with High Affinity* , 2016, The Journal of Biological Chemistry.

[4]  S. Katzav.  Vav1: A Dr. Jekyll and Mr. Hyde protein – good for the hematopoietic system, bad for cancer , 2015, Oncotarget.

[5]  J. Das,et al.  Modeling studies on the structural determinants for the DAG/phorbol ester binding to C1 domain , 2015, Journal of biomolecular structure & dynamics.

[6]  D. Alkon,et al.  Common mechanisms of Alzheimer's disease and ischemic stroke: the role of protein kinase C in the progression of age-related neurodegeneration. , 2014, Journal of Alzheimer's disease : JAD.

[7]  J. Das,et al.  C1 domains: structure and ligand-binding properties. , 2014, Chemical reviews.

[8]  V. Sanz-Moreno,et al.  Rho GTPases modulate malignant transformation of tumor cells , 2014, Small GTPases.

[9]  A. Altman,et al.  Protein kinase C inhibitors for immune disorders. , 2014, Drug discovery today.

[10]  X. Bustelo.  Vav family exchange factors: an integrated regulatory and functional view , 2014, Small GTPases.

[11]  Megan L. Peach,et al.  Diacylglycerol Lactones Targeting the Structural Features That Distinguish the Atypical C1 Domains of Protein Kinase C ζ and ι from Typical C1 Domains , 2014, Journal of medicinal chemistry.

[12]  Baljinder K. Grewal,et al.  Protein kinase C inhibitors: a patent review (2010 – present) , 2013, Expert opinion on therapeutic patents.

[13]  J. Kuriyan,et al.  Structural analysis of autoinhibition in the Ras-specific exchange factor RasGRP1 , 2013, eLife.

[14]  Y. Yang,et al.  The N-terminal 20-Amino Acid Region of Guanine Nucleotide Exchange Factor Vav1 Plays a Distinguished Role in T Cell Receptor-mediated Calcium Signaling* , 2012, The Journal of Biological Chemistry.

[15]  J. Kulkosky,et al.  Protein Kinase C: One Pathway towards the Eradication of Latent HIV-1 Reservoirs , 2012, Advances in virology.

[16]  Baljinder K. Grewal,et al.  Protein kinase C βII in diabetic complications: survey of structural, biological and computational studies , 2012, Expert opinion on therapeutic targets.

[17]  Megan L. Peach,et al.  Molecular Basis for Failure of “Atypical” C1 Domain of Vav1 to Bind Diacylglycerol/Phorbol Ester* , 2012, The Journal of Biological Chemistry.

[18]  Julio C. B. Ferreira,et al.  βIIPKC and εPKC isozymes as potential pharmacological targets in cardiac hypertrophy and heart failure. , 2011, Journal of molecular and cellular cardiology.

[19]  Aurélien Grosdidier,et al.  Fast docking using the CHARMM force field with EADock DSS , 2011, J. Comput. Chem..

[20]  Aurélien Grosdidier,et al.  SwissDock, a protein-small molecule docking web service based on EADock DSS , 2011, Nucleic Acids Res..

[21]  G. Hummer,et al.  Crystal Structure and Allosteric Activation of Protein Kinase C βII , 2011, Cell.

[22]  A. Newton,et al.  Protein kinase C: poised to signal. , 2010, American journal of physiology. Endocrinology and metabolism.

[23]  R. Sharan,et al.  I-TASSER: a unified platform for automated protein structure and function prediction , 2010, Nature Protocols.

[24]  M. Kazanietz,et al.  ROCK Mediates Phorbol Ester-induced Apoptosis in Prostate Cancer Cells via p21Cip1 Up-regulation and JNK* , 2009, The Journal of Biological Chemistry.

[25]  S. Katzav.  Vav1: a hematopoietic signal transduction molecule involved in human malignancies. , 2009, The international journal of biochemistry & cell biology.

[26]  R. Stahelin.  Lipid binding domains: more than simple lipid effectors This research was supported by grants from the American Heart Association (0735350N), the American Cancer Society (IRG-84-002-22), and the Indiana University School of Medicine. Published, JLR Papers in Press, November 13, 2008. , 2009, Journal of Lipid Research.

[27]  S. Steinberg.  Structural basis of protein kinase C isoform function. , 2008, Physiological reviews.

[28]  Megan L. Peach,et al.  Conformationally constrained analogues of diacylglycerol. 29. Cells sort diacylglycerol-lactone chemical zip codes to produce diverse and selective biological activities. , 2008, Journal of medicinal chemistry.

[29]  Megan L. Peach,et al.  Wealth of opportunity - the C1 domain as a target for drug development. , 2008, Current drug targets.

[30]  K. Rittinger,et al.  Crucial structural role for the PH and C1 domains of the Vav1 exchange factor , 2008, EMBO reports.

[31]  M. Kazanietz,et al.  Protein kinase C and other diacylglycerol effectors in cancer , 2007, Nature Reviews Cancer.

[32]  Megan L. Peach,et al.  Effects on Ligand Interaction and Membrane Translocation of the Positively Charged Arginine Residues Situated along the C1 Domain Binding Cleft in the Atypical Protein Kinase C Isoforms* , 2006, Journal of Biological Chemistry.

[33]  M. Kazanietz,et al.  C1 domains exposed: from diacylglycerol binding to protein-protein interactions. , 2006, Biochimica et biophysica acta.

[34]  Megan L. Peach,et al.  Conformationally constrained analogues of diacylglycerol (DAG). 25. Exploration of the sn-1 and sn-2 carbonyl functionality reveals the essential role of the sn-1 carbonyl at the lipid interface in the binding of DAG-lactones to protein kinase C. , 2005, Journal of medicinal chemistry.

[35]  L. Saidi,et al.  Structural Mechanism for Lipid Activation of the Rac-Specific GAP, β2-Chimaerin , 2004, Cell.

[36]  Robert V. Stahelin,et al.  Mechanism of Diacylglycerol-induced Membrane Targeting and Activation of Protein Kinase Cθ* , 2004, Journal of Biological Chemistry.

[37]  G. Spiegelman,et al.  Chemoattractant‐induced Ras activation during Dictyostelium aggregation , 2004, EMBO reports.

[38]  P. Blumberg,et al.  Synthetic diacylglycerols (DAG) and DAG-lactones as activators of protein kinase C (PK-C). , 2003, Accounts of chemical research.

[39]  X. Bustelo,et al.  Structural Determinants for the Biological Activity of Vav Proteins* , 2002, The Journal of Biological Chemistry.

[40]  U. Kikkawa,et al.  Establishment of a binding assay for protein kinase C isozymes using synthetic C1 peptides and development of new medicinal leads with protein kinase C isozyme and C1 domain selectivity. , 2002, Pharmacology & therapeutics.

[41]  X. Bustelo.  Vav proteins, adaptors and cell signaling , 2001, Oncogene.

[42]  B Bienfait,et al.  Conformationally constrained analogues of diacylglycerol (DAG). 16. How much structural complexity is necessary for recognition and high binding affinity to protein kinase C? , 2000, Journal of medicinal chemistry.

[43]  X. Bustelo,et al.  Biological and Regulatory Properties of Vav-3, a New Member of the Vav Family of Oncoproteins , 1999, Molecular and Cellular Biology.

[44]  Y. Nishizuka,et al.  Taxonomy and function of C1 protein kinase C homology domains , 1997, Protein science : a publication of the Protein Society.

[45]  H. Mott,et al.  The solution structure of the Raf-1 cysteine-rich domain: a novel ras and phospholipid binding site. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[46]  B. Neel,et al.  Solubilization and purification of enzymatically active glutathione S-transferase (pGEX) fusion proteins. , 1993, Analytical biochemistry.

[47]  P. Blumberg,et al.  [ 3 H]Phorbol 12,13-Dibutyrate Binding Assay for Protein Kinase C and Related Proteins , 2003 .

[48]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[49]  C. Chuong,et al.  Article type Software , 2007 .